34 results about "Cytosine nucleotide" patented technology

The present application relates to a kind of metabolic markers for diagnosing diabetes secondary osteoporosis and its application, belong to biological medicine technical field.The present application first selects the significant difference metabolite between the group of diabetes mellitus patients with osteoporosis (DOP) and the group without osteoporosis (DM);Second, the significant difference metabolite between the group of primary osteoporosis patients and the group of healthy controls is screened out, and the intersection of the two groups of difference metabolites is excluded, and the obtained metabolite excludes the influence of primary osteoporosis.Subsequently, the metabolic markers of the present application-cytidine nucleotide, ketoglutaric acid, triethylamine are further screened, and when the three kinds of metabolic markers are used alone, the AUC is greater than 0.8, and when the three kinds of metabolic markers are used in combination, the AUC is 0.99, effectively making up the limitation of traditional bone density detection in the population of diabetes mellitus patients to identify osteoporosis.